Diamyd Medical AB (publ) Stock Nasdaq Stockholm
Equities
SE0005162880
Biotechnology & Medical Research
Sales 2024 * | 3M 272K | Sales 2025 * | 3M 272K | Capitalization | 1.1B 99.46M |
---|---|---|---|---|---|
Net income 2024 * | -133M -12.07M | Net income 2025 * | -165M -14.97M | EV / Sales 2024 * | 319 x |
Net cash position 2024 * | 139M 12.61M | Net cash position 2025 * | 30M 2.72M | EV / Sales 2025 * | 355 x |
P/E ratio 2024 * |
-8.03
x | P/E ratio 2025 * |
-6.47
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 72.91% |
Latest transcript on Diamyd Medical AB (publ)
Managers | Title | Age | Since |
---|---|---|---|
Ulf Hannelius
CEO | Chief Executive Officer | 49 | 16-04-09 |
Founder | 83 | 95-12-31 | |
Anna Styrud
DFI | Director of Finance/CFO | 63 | 09-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 83 | 95-12-31 | |
Director/Board Member | 63 | 11-12-31 | |
Director/Board Member | 52 | 21-04-27 |
1st Jan change | Capi. | |
---|---|---|
-3.46% | 102B | |
+1.41% | 96.29B | |
+2.13% | 22.18B | |
-15.84% | 21.2B | |
-9.21% | 18.31B | |
-39.98% | 17.38B | |
-14.65% | 16.36B | |
+4.39% | 13.97B | |
+31.35% | 12.17B |